AI assistant
IDEAYA Biosciences, Inc. — Director's Dealing 2021
Aug 11, 2021
31547_dirs_2021-08-11_5520b61a-f827-4c0a-bf63-891d420ffef7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEAYA Biosciences, Inc. (IDYA)
CIK: 0001676725
Period of Report: 2021-08-09
Reporting Person: Dillon Michael P. (SVP, Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-09 | Common Stock | M | 1500 | $4.31 | Acquired | 100289 | Direct |
| 2021-08-09 | Common Stock | S | 11100 | $22.9606 | Disposed | 89189 | Direct |
| 2021-08-09 | Common Stock | S | 400 | $23.515 | Disposed | 88789 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-09 | Stock Option (Right to Buy) | $4.31 | M | 1500 | Disposed | 2028-02-26 | Common Stock (1500) | Direct |
Footnotes
F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades in prices ranging from $22.48 to $23.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: This transaction was executed in multiple trades in prices ranging from $23.49 to $23.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.